The Crossover: How FGF21 Became the Cardiometabolic Layer Beneath GLP-1

The Crossover: How FGF21 Became the Cardiometabolic Layer Beneath GLP-1

Published Date: 06.30.2026

Everyone saw the GLP-1 revolution. A few saw what happened next. While the industry focused on weight loss, Novo Nordisk, Roche, and GSK quietly committed more than $10.7 billion to FGF21. They weren't buying another obesity drug; they were investing in the next layer of cardiometabolic innovation. This PatentVest Pulse report explores why that shift matters and what it means for the companies building, protecting, and investing in the future of metabolic disease.

READ FULL REPORT

Past performance is no guarantee of future results. Investing involves risk, including loss of principal. All corporate names, trading symbols, and market data displayed in the report are for illustrative purposes only and are not intended to portray recommendations. Information in this report from third parties has been obtained from sources believed to be reliable and accurate; however, neither MDB Capital nor its affiliates warrant its accuracy and assume no responsibility for any errors or omissions. This post is for informational purposes only and does not constitute an offer or solicitation for any security or investment service. MDB Capital, Member FINRA/SIPC.